CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen ...

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the ...

Initiating intensive blood pressure lowering soon after ICH is linked to better outcomes compared to currently recommended ...

Obesity is a global health crisis with profound clinical and societal consequences, contributing to increased risks of ...

Any deal of that size, though, takes time. As such we find ourselves nearing the end of a second week of knowing Liverpool are pushing to sign Bayer Leverkusen and Germany 22-year-old attacker ...

On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock’s ...

Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) settled +4.4% in Frankfurt trading Thursday as Goldman Sachs upgraded shares to Buy from neutral with a €33 price target, raised from €29.10 previously ...

CC acknowledges grants or contracts from Echosens, Gilead, and Novo Nordisk, consulting fees from Gilead, Novo Nordisk, AstraZeneca, Elli Lilly, E-scopics, MSD, Bayer, and Echosens, payment or ...

The American medicines regulator has approved Bayer’s (BAYN: DE) Nubeqa (darolutamide) for broader use in patients with metastatic castration-sensitive prostate cancer (mCSPC), marking a step forward ...

ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST           U.S. FDA approves third indication of darolutamide for patients with ...